John Kyriakis

 

John Kyriakis 

Mercury Therapeutics 

Vice President for Research 

Contact Information:
Mercury Therapeutics
175E New Boston Street
Woburn, MA 01801
Tel: 781-932-1125, ext. 26
E-mail:
jkyriakis@asbmb.org  

I am currently Vice President for Research at Mercury Therapeutics, a small pharmaceutical company that develops novel treatments for metabolic diseases and cancer. With our partners Debiopharm, we have discovered a new compound, currently in the GLP-Tox stage of development, that strongly activates the 5'AMP-activated kinase to ameliorate type-2 diabetes. Prior to working at Mercury, I was an academic scientist at Massachusetts General Hospital (1987-2002) and Tufts Medical Center (2002-2012). My major work focused on MAPK pathways and included discovery of the JNKs and identification of MEK as a substrate for Raf. My lab also worked on the Hippo tumor suppressor pathway.

Outreach 

I am working with POC to coordinate outreach with the advocacy activities of the ASBMB Public Affairs Advisory Committee (of which I am also a member).